Investegate |Santhera Pharmaceuticals Holdi Announcements |

Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Related Keywords

Norway , Iceland , Pratteln , Switzerland General , Switzerland , United States , United Kingdom , Liechtenstein , France , America , Swiss , Eric Hoffman , Eva Kalias , Reveragen Biopharma , Dario Eklund , Life Science Alliance , Muscular Dystrophy Association United States , Santhera Pharmaceuticals Holding , Head Investor Relations Communications , European Union , Reveragen Biopharma Inc , Santhera Pharmaceuticals , National Institutes Of Health , Drug Administration , Foundation To Eradicate Duchenne , Duchenne Research Fund , European Commission Horizons , Chiesi Group , European Medicines Agency , Us Department Of Defense , Reveragen Complete , Duchenne Muscular , Orphan Drug , Fast Track , Rare Pediatric Disease , Promising Innovative Medicine , Proc Natl Acad Sci United States , North America , Parent Project Muscular Dystrophy , Eradicate Duchenne , Save Our Sons , Action Duchenne , Defeat Duchenne , National Institutes , European Commission , Head Investor Relations , Investegate Announcements , Investegate Company Announcements , Anthera Pharmaceuticals Holdi , Lobenewswire , Lobenewswire And Globenewswire , Nw ,